Soleno Therapeutics (SLNO) Gains from Investment Securities (2016 - 2019)
Historic Gains from Investment Securities for Soleno Therapeutics (SLNO) over the last 7 years, with Q4 2019 value amounting to $7.9 million.
- Soleno Therapeutics' Gains from Investment Securities rose 48116.85% to $7.9 million in Q4 2019 from the same period last year, while for Dec 2019 it was $7.0 million, marking a year-over-year increase of 47141.33%. This contributed to the annual value of $2.8 million for FY2024, which is 37487.44% up from last year.
- Per Soleno Therapeutics' latest filing, its Gains from Investment Securities stood at $7.9 million for Q4 2019, which was up 48116.85% from -$7.1 million recorded in Q3 2019.
- Soleno Therapeutics' 5-year Gains from Investment Securities high stood at $7.9 million for Q4 2019, and its period low was -$7.1 million during Q3 2019.
- Its 5-year average for Gains from Investment Securities is $273182.9, with a median of $50000.0 in 2016.
- As far as peak fluctuations go, Soleno Therapeutics' Gains from Investment Securities crashed by 52265.31% in 2018, and later soared by 127730.06% in 2019.
- Soleno Therapeutics' Gains from Investment Securities (Quarter) stood at $515860.0 in 2015, then plummeted by 432.67% to -$1.7 million in 2016, then skyrocketed by 128.55% to $490000.0 in 2017, then plummeted by 522.65% to -$2.1 million in 2018, then surged by 481.17% to $7.9 million in 2019.
- Its Gains from Investment Securities was $7.9 million in Q4 2019, compared to -$7.1 million in Q3 2019 and $4.3 million in Q2 2019.